Updated on 2021/11/08

写真a

 
ISHIKAWA Yuichi
 
Organization
Nagoya University Hospital Hematology Lecturer of hospital
Title
Lecturer of hospital

Degree 1

  1. 博士(医学) ( 2009.5   名古屋大学 ) 

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    - 2009.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    - 2000.3

      More details

    Country: Japan

Professional Memberships 5

  1. 日本血液学会   評議員

  2. 日本内科学会

  3. 日本癌学会

  4. 日本臨床腫瘍学会

  5. The American Society of Hematology

Awards 1

  1. 日本血液学会奨励賞

    2008   日本血液学会  

     More details

    Country:Japan

 

Papers 48

  1. Recent advances in molecular targeted therapy for acute myeloid leukemia Invited Reviewed

    Yuichi Ishikawa

        2021.6

     More details

    Authorship:Lead author, Corresponding author  

  2. Clinical significance of MRD in AML Invited Reviewed

    Yuichi Ishikawa

        2020.9

  3. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults withFLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study Reviewed

    Kawashima Naomi, Ishikawa Yuichi, Atsuta Yoshiko, Sawa Masashi, Ozawa Yukiyasu, Hayashi Masaki, Kohno Akio, Tomita Akihiro, Maeda Tomoya, Sakaida Emiko, Usuki Kensuke, Hagihara Maki, Kanamori Heiwa, Matsuoka Hiroshi, Kobayashi Miki, Asou Norio, Ohtake Shigeki, Matsumura Itaru, Miyazaki Yasushi, Naoe Tomoki, Kiyoi Hitoshi

    CANCER SCIENCE   Vol. 111 ( 7 ) page: 2472 - 2481   2020.7

  4. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL) Reviewed

    Fujita Hiroyuki, Ishikawa Yuichi, Yokoyama Yasuhisa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 111 ( 6 ) page: 747 - 760   2020.6

  5. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development Reviewed

    Kiyoi Hitoshi, Kawashima Naomi, Ishikawa Yuichi

    CANCER SCIENCE   Vol. 111 ( 2 ) page: 312 - 322   2020.2

     More details

    Authorship:Last author  

    DOI: 10.1111/cas.14274

    Web of Science

  6. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Reviewed

    Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H.

    BLOOD ADVANCES     2020.1

     More details

    Authorship:Lead author  

  7. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation

    Goto Tatsunori, Murata Makoto, Nishida Tetsuya, Terakura Seitaro, Kamoshita Sonoko, Ishikawa Yuichi, Ushijima Yoko, Adachi Yoshiya, Suzuki Satoshi, Kato Katsuyoshi, Hirakawa Akihiro, Nishiwaki Satoshi, Nishio Nobuhiro, Takahashi Yoshiyuki, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi

    STEM CELLS TRANSLATIONAL MEDICINE     2020.12

  8. Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features Reviewed

    Nishiwaki Satoshi, Kim Jeong Hui, Ito Masafumi, Maeda Matsuyoshi, Okuno Yusuke, Koyama Daisuke, Ozawa Yukiyasu, Gunji Masaharu, Osaki Masahide, Kitamura Kunio, Ushijima Yoko, Ishikawa Yuichi, Miyamura Koichi, Sugiura Isamu, Kiyoi Hitoshi

    FRONTIERS IN ONCOLOGY   Vol. 10   2020.10

  9. Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study. Reviewed

    Yasuda T, Sanada M, Nishijima D, Kanamori T, Iijima Y, Hattori H, Saito A, Miyoshi H, Ishikawa Y, Asou N, Usuki K, Hirabayashi S, Kato M, Ri M, Handa H, Ishida T, Shibayama H, Abe M, Iriyama C, Karube K, Nishikori M, Ohshima K, Kataoka K, Yoshida K, Shiraishi Y, Goto H, Adachi S, Kobayashi R, Kiyoi H, Miyazaki Y, Ogawa S, Kurahashi H, Yokoyama H, Manabe A, Iida S, Tomita A, Horibe K

    CANCER SCIENCE     2020

  10. New TARGET investigators. Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line Reviewed

    Sakurai M, Okamoto S, Matsumura I, Murakami S, Takizawa M, Waki M, Hirano D, Watanabe-Nakaseko R, Kobayashi N, Iino M, Mitsui H, Ishikawa Y, Takahashi N, Kawaguchi T, Suzuki R, Yamamoto K, Kizaki M, Ohnishi K, Naoe T, Akashi K

    INTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 111   page: 812 - 825   2020

  11. Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells

    Goto Tatsunori, Murata Makoto, Nishida Tetsuya, Terakura Seitaro, Kamoshita Sonoko, Ishikawa Yuichi, Ushijima Yoko, Adachi Yoshiya, Kato Katsuyoshi, Hirakawa Akihiro, Nishiwaki Satoshi, Nishio Nobuhiro, Takahashi Yoshiyuki, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi

    BLOOD   Vol. 134   2019.11

  12. Development of Predictive Biomarker and Optimal Treatment Strategy with FLT3 Inhibitors in Acute Myeloid Leukemia

    Kim Jeong Hui, Harada Yasuhiko, Ishikawa Yuichi, Kawashima Naomi, Nakashima Marie, Ushijima Yoko, Nishiyama Takahiro, Goto Tatsunori, Fukushima Nobuaki, Kihara Rika, Kajiguchi Tomohiro, Watamoto Koichi, Kohno Akio, Kitamura Kunio, Ozawa Yukiyasu, Kiyoi Hitoshi

    BLOOD   Vol. 134   2019.11

  13. FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

    Ishikawa Yuichi, Saito Koichi, Kawashima Naomi, Morimoto Michie, Murao Hidetoshi, Terada Daisuke, Yamaura Takeshi, Hagiwara Shinji, Kiyoi Hitoshi

    BLOOD   Vol. 134   2019.11

  14. Dynamics of Genetic Landscapes and Clonal Evolution between Patients and PDX Models in Acute Myeloid Leukemia

    Kawashima Naomi, Ishikawa Yuichi, Akashi Akimi, Hattori Hikaru, Yamaguchi Yohei, Nishiyama Takahiro, Kihara Rika, Ozawa Yukiyasu, Kiyoi Hitoshi

    BLOOD   Vol. 132   2018.11

  15. Anti-Leukemic Effect of Retinoic Acid in Non-APL AML Cells

    Harada Yasuhiko, Ishikawa Yuichi, Kawashima Naomi, Hattori Hikaru, Yamaguchi Yohei, Adachi Yoshiya, Ushijima Yoko, Kiyoi Hitoshi

    BLOOD   Vol. 132   2018.11

  16. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia Reviewed

    Hattori Hikaru, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Yamaguchi Yohei, Harada Yasuhiko, Hirano Daiki, Adachi Yoshiya, Miyao Kotaro, Ushijima Yoko, Terakura Seitaro, Nishida Tetsuya, Matsushita Tadashi, Kiyoi Hitoshi

    PLOS ONE   Vol. 13 ( 10 ) page: e0204850   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0204850

    Web of Science

    PubMed

  17. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Reviewed

    Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H, Japan Adult Leukemia Study Group (JALSG).

    Annals of hematology     2018.9

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00277-018-3492-5

    PubMed

  18. Mutation analysis of therapy-related myeloid neoplasms Reviewed

    Nishiyama Takahiro, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Adachi Yoshiya, Hattori Hikaru, Ushijima Yoko, Kiyoi Hitoshi

    CANCER GENETICS   Vol. 222   page: 38 - 45   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cancergen.2018.02.006

    Web of Science

    PubMed

  19. Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol

    Goto Tatsunori, Murata Makoto, Terakura Seitaro, Nishida Tetsuya, Adachi Yoshiya, Ushijima Yoko, Shimada Kazuyuki, Ishikawa Yuichi, Hayakawa Fumihiko, Nishio Nobuhiro, Nishiwaki Satoshi, Hirakawa Akihiro, Kato Katsuyoshi, Takahashi Yoshiyuki, Kiyoi Hitoshi

    MEDICINE   Vol. 97 ( 17 ) page: e0449   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/MD.0000000000010449

    Web of Science

    PubMed

  20. Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.

    Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, Al-Raqad M, Maeda M, Schoonenberg VAC, Cole MA, Macias-Trevino C, Ishikawa Y, Yao Q, Nakano M, Arai F, Orkin SH, Reversade B, Buonamici S, Pinello L, Akashi K, Bauer DE, Maeda T

    Cancer cell   Vol. 33 ( 3 ) page: 386-400.e5   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ccell.2018.01.012

    PubMed

  21. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study Reviewed

    Harada Yasuhiko, Nagata Yasunobu, Kihara Rika, Ishikawa Yuichi, Asou Norio, Ohtake Shigeki, Miyawaki Shuichi, Sakura Toru, Ozawa Yukiyasu, Usui Noriko, Kanamori Heiwa, Ito Yoshikazu, Imai Kiyotoshi, Suehiro Youko, Kobayashi Shinichi, Kitamura Kunio, Sakaida Emiko, Onizuka Makoto, Takeshita Akihiro, Ishida Fumihiro, Suzushima Hitoshi, Ishizawa Kenichi, Naoe Tomoki, Matsumura Itaru, Miyazaki Yasushi, Ogawa Seishi, Kiyoi Hitoshi

    LEUKEMIA RESEARCH   Vol. 66   page: 20-27   2018.3

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.leukres.2018.01.008

    Web of Science

    PubMed

  22. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

    Yamaura Takeshi, Nakatani Toshiyuki, Uda Ken, Ogura Hayato, Shin Wigyon, Kurokawa Naoya, Saito Koichi, Fujikawa Norie, Date Tomomi, Takasaki Masaru, Terada Daisuke, Hirai Atsushi, Akashi Akimi, Chen Fangli, Adachi Yoshiya, Ishikawa Yuichi, Hayakawa Fumihiko, Hagiwara Shinji, Naoe Tomoki, Kiyoi Hitoshi

    BLOOD   Vol. 131 ( 4 ) page: 426 - 438   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1182/blood-2017-05-786657

    Web of Science

    PubMed

  23. Intrabone single unit cord blood transplantation for hematological malignancies

    Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Fukuhara Noriko, Nishida Tetsuya, Terakura Seitaro, Ishikawa Yuichi, Tanimoto Mitsune, Shibasaki Yasuhiko, Suzuki Ritsuro, Kodera Yoshihisa, Kiyoi Hitoshi, Naoe Tomoki

    CANCER SCIENCE   Vol. 109   page: 757-757   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  24. Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia Invited Reviewed

      Vol. 59 ( 10 ) page: 1997-2006   2018

     More details

    Authorship:Lead author   Language:Japanese  

    DOI: 10.11406/rinketsu.59.1997

    PubMed

  25. [MonoMAC syndrome patient developing myelodysplastic syndrome following persistent EBV infection].

    Yamamoto H, Hattori H, Takagi E, Morishita T, Ishikawa Y, Terakura S, Nishida T, Ito Y, Murata M, Kiyoi H

    [Rinsho ketsueki] The Japanese journal of clinical hematology   Vol. 59 ( 3 ) page: 315-322   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.59.315

    PubMed

  26. Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia

    Adachi Yoshiya, Ishikawa Yuichi, Kiyoi Hitoshi

    ONCOTARGET   Vol. 8 ( 45 ) page: 78452 - 78465   2017.10

  27. Abscopal Effect of Local Irradiation Treatment for Diffuse Large B-cell Lymphoma

    Hidaka Yuri, Takeichi Takuya, Ishikawa Yuichi, Kawamura Mariko, Akiyama Masashi

    ACTA DERMATO-VENEREOLOGICA   Vol. 97 ( 9 ) page: 1140-1141   2017.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2340/00015555-2729

    Web of Science

    PubMed

  28. Core-binding factor白血病における遺伝子異常 Invited Reviewed

    石川裕一

    臨床血液   Vol. 58 ( 8 ) page: 991-998   2017.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  29. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies

    Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Onishi Yasushi, Endo Tomoyuki, Terakura Seitaro, Ishikawa Yuichi, Iriyama Chisako, Ushijima Yoko, Goto Tatsunori, Fujii Nobuharu, Tanimoto Mitsune, Kobayashi Hironori, Shibasaki Yasuhiko, Fukuhara Noriko, Inamoto Yoshihiro, Suzuki Ritsuro, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi, Naoe Tomoki, Nishida Tetsuya

    CANCER SCIENCE   Vol. 108 ( 8 ) page: 1634 - 1639   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13291

    Web of Science

    PubMed

  30. Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia Reviewed

      Vol. 8 ( 45 ) page: 78452-78465   2017.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  31. Malignant lymphoma with cardiac involvement.

    Terakura S, Onji M, Iriyama C, Goto T, Ushijima Y, Shimada K, Ishikawa Y, Nishida T, Hayakawa F, Murata M, Kiyoi H

    [Rinsho ketsueki] The Japanese journal of clinical hematology   Vol. 58 ( 3 ) page: 239-242   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.58.239

    PubMed

  32. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells Reviewed

    Fangli Chen, Yuichi Ishikawa, Akimi Akashi, Tomoki Naoe and Hitoshi Kiyoi

      Vol. 7 ( 30 ) page: 47018-32   2016.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  33. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology Reviewed

    Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T

    Haematologica   Vol. 100 ( 4 ) page: 439-51   2015.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  34. Snx3 Regulates Recycling of the Transferrin Receptor and Iron Assimilation Reviewed

    Chen C, Garcia-Santos D, Ishikawa Y, Seguin A, Li L, Fegan KH, Hildick-Smith GJ, Shah DI, Cooney JD, Chen W, King MJ, Yien YY, Schultz IJ, Anderson H, Dalton AJ, Freedman ML, Kingsley PD, Palis J, Hattangadi SM, Lodish HF, Ward DM, Kaplan J, Maeda T, Ponka P, Paw BH

    Cell Metab.   Vol. 17 ( 3 ) page: 343-52   2013.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  35. LRF-mediated Dll4 repression in erythroblasts is necessary for hematopoietic stem cell maintenance Reviewed

    Lee SU, Maeda M, Ishikawa Y, Li SM, Wilson A, Jubb AM, Sakurai N, Weng L, Fiorini E, Radtke F, Yan M, Macdonald HR, Chen CC, Maeda T

    Blood.   Vol. 121 ( 6 ) page: 918-929   2013.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  36. GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. Reviewed

    Niimi K, Kiyoi H, Ishikawa Y, Hayakawa F, Kurahashi S, Kihara R, Tomita A, Naoe T

    Leukemia research reports   Vol. 2 ( 1 ) page: 21-5   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lrr.2013.02.002

    PubMed

  37. The LRF transcription factor regulates mature B cell development and the germinal center response in mice Reviewed

    Sakurai N, Maeda M, Lee SU, Ishikawa Y, Li M, Williams JC, Wang L, Su L, Suzuki M, Saito TI, Chiba S, Casola S, Yagita H, Teruya-Feldstein J, Tsuzuki S, Bhatia R, Maeda T

    J Clin Invest.   Vol. 121 ( 7 ) page: 2583-98   2011.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  38. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia Reviewed

    Ishikawa Y, Kiyoi H, Naoe T

    Leuk Res.   Vol. 35 ( 5 ) page: 685-8   2011.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  39. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis Reviewed

    Sakai K, Ishikawa Y, Mori Y, Kobayashi M, Iriyama C, Ozawa Y, Suzuki T, Minami Y, Ishikawa K, Kaneda N, Naoe T, Kiyoi H

    Int J Hematol.   Vol. 93 ( 2 ) page: 237-42   2011.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  40. Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. Reviewed

    Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T

    International journal of hematology   Vol. 92 ( 4 ) page: 624-33   2010.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-010-0692-8

    PubMed

  41. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study Reviewed

    Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K, Naoe T

    Cancer Sci.   Vol. 101 ( 10 ) page: 2186-92   2010.10

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  42. Array-based genomic resequencing of human leukemia. Reviewed

    Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, Ueno T, Soda M, Hamada T, Haruta H, Takada S, Miyazaki Y, Kiyoi H, Ito E, Naoe T, Tomonaga M, Toyota M, Tajima S, Iwama A, Mano H

    Oncogene   Vol. 29 ( 25 ) page: 3723-31   2010.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/onc.2010.117

    PubMed

  43. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation Reviewed

    Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H, Ishii K, Mori Y, Ozeki K, Minami Y, Abe A, Maeda H, Akiyama T, Kanda Y, Sato Y, Akinaga S, Naoe T

    Blood.   Vol. 114 ( 8 ) page: 1607-17   2009.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  44. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia Reviewed

    Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, Tomonaga M, Naoe T

    Eur J Haematol.   Vol. 83 ( 2 ) page: 90-98   2009.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  45. Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes Reviewed

    Ishikawa Y, Xu J, Sakashita G, Urano T, Suzuki T, Tomita A, Kiyoi H, Nakamura S, Naoe T

    Leuk Lymphoma. 49   Vol. 49 ( 12 ) page: 2359-64   2009.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  46. WHO分類に基づく急性骨髄性白血病における網羅的遺伝子変異の解析 Invited Reviewed

    石川裕一

    臨床血液   Vol. 50 ( 8 ) page: 597-603   2009

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  47. Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. Reviewed

    Iwasaki T, Katsumi A, Kiyoi H, Tanizaki R, Ishikawa Y, Ozeki K, Kobayashi M, Abe A, Matsushita T, Watanabe T, Amano M, Kojima T, Kaibuchi K, Naoe T

    European journal of haematology   Vol. 81 ( 6 ) page: 454-60   2008.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1600-0609.2008.01132.x

    PubMed

  48. Mutational analysis of SOS1 gene in acute myeloid leukemia. Reviewed

    Tanizaki R, Katsumi A, Kiyoi H, Kunishima S, Iwasaki T, Ishikawa Y, Kobayashi M, Abe A, Matsushita T, Watanabe T, Kojima T, Kaibuchi K, Kojima S, Naoe T

    International journal of hematology   Vol. 88 ( 4 ) page: 460-2   2008.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-008-0185-1

    PubMed

▼display all

Books 20

  1. 血液内科「再発・難治性AMLに対する治療戦略」

    石川 裕一

    科学評論社  2021.8 

  2. 血液内科「CBF関連転座を有する急性骨髄性白血病の予後と治療」

    石川 裕一

    科学評論社  2020.4 

  3. EBM 血液疾患の治療 2021-2022

    石川裕一、清井仁( Role: Contributor ,  骨髄系腫瘍に対するクリニカルシーケンス)

    中外医学社  2020 

  4. 白血病治療マニュアル改訂第4版

    石川裕一( Role: Contributor ,  fit初発例の治療プロトコール)

    南江堂  2020 

  5. 日本臨床 造血器腫瘍学

    石川裕一、清井仁( Role: Contributor ,  分子標的療法(TKI, エピジェネティック修飾, PI, IMIDs含む))

    日本臨床社  2020 

  6. 急性白血病診療テキスト

    石川裕一( Role: Contributor ,  急性骨髄性白血病 染色体・遺伝子異常)

    中外医学社  2020 

  7. 内科「白血病の治療 急性骨髄性白血病」

    石川 裕一

    南江堂  2019.10 

  8. 臨床検査「急性リンパ芽球性白血病(前駆リンパ球性腫瘍)の遺伝子異常」

    石川 裕一

    医学書院  2019.7 

  9. 血液疾患 最新の治療 2020-2022

    石川裕一( Role: Contributor ,  急性骨髄性白血病)

    南江堂  2019 

  10. WHO血液腫瘍分類 WHO分類2017をうまく活用するために 「NPM1遺伝子変異を伴う急性骨髄性白血病」 「両アレルのCEBPA遺伝子変異を伴う急性骨髄性白血病」

    石川裕一( Role: Sole author)

    医薬ジャーナル社  2018.10 

     More details

    Language:Japanese Book type:Scholarly book

  11. 血液内科「成人急性骨髄性白血病における遺伝子変異による微小残存病変の検出とその意義」

    石川裕一, 清井仁( Role: Joint author)

    科学評論社  2018.5 

     More details

    Language:Japanese Book type:Scholarly book

  12. メディカル・サイエンス・ダイジェスト 「急性骨髄性白血病の病態解明と分子標的治療」

    石川 裕一( Role: Sole author)

    ニューサイエンス社  2017.7 

     More details

    Total pages:4   Language:Japanese Book type:Scholarly book

  13. 日本臨床 白血病学(上)「遺伝子突然変異による骨髄性腫瘍の発症機序:概論」

    石川 裕一、清井 仁( Role: Joint author)

    日本臨牀社  2016.10 

     More details

    Total pages:8   Language:Japanese Book type:Scholarly book

  14. 造血器腫瘍アトラス 改訂第5版 「急性白血病の遺伝子異常」

    石川 裕一, 清井 仁( Role: Joint author)

    日本医事新報社  2016.7 

     More details

    Language:Japanese Book type:Scholarly book

  15. Annual Review 血液 2016 「異常転写因子(CBFβ-SMMHC)を標的とした急性骨髄性白血病に対する新規治療薬の開発」

    石川裕一、清井仁( Role: Joint author)

    中外医学社  2016.1 

     More details

    Language:Japanese Book type:Scholarly book

  16. 腫瘍内科 「AMLの予後解析 -Simpson's paradox-」

    石川裕一、清井仁( Role: Joint author)

    科学評論社  2015.12 

     More details

    Language:Japanese Book type:Scholarly book

  17. 血液疾患 診断・治療指針 「急性骨髄性白血病 (non-APL)」

    石川 裕一, 清井 仁( Role: Joint author)

    中山書店  2015.10 

     More details

    Total pages:9   Language:Japanese Book type:Scholarly book

  18. 血液内科 「AML/MDSに対する新規低分子化合物の現状と展望」

    石川裕一、清井仁( Role: Joint author)

    科学評論社  2015.2 

     More details

    Language:Japanese

  19. Annual Review 血液 2015 「急性骨髄性白血病のゲノム解析」

    石川裕一、清井仁( Role: Sole author)

    中外医学社  2015.1 

     More details

    Language:Japanese

  20. 血液フロンティア 「急性白血病のクローン性」

    石川裕一、清井仁( Role: Joint author)

    医薬ジャーナル社  2014.6 

     More details

    Language:Japanese

▼display all

Presentations 12

  1. Recent developments and challenges of FLT3 inhibitors in AML Invited

    Yuichi Ishikawa

    The 59th Annual Meeting of the Japanese Society of Clinical Oncology  2021.10.21 

     More details

    Event date: 2021.10

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  2. 急性骨髄性白血病におけるMRDの意義 Invited

    石川裕一

    第82回日本血液学会学術集会  2020.10  日本血液学会

     More details

    Event date: 2020.10

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

  3. FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens International conference

    Y Ishikawa, K Saito, N Kawashima, M Morimoto, H Murao, D Terada, T Yamaura, S Hagiwara, H Kiyoi

    61th American Society of Hematology Annual Meeting and Exposition  2019.12 

     More details

    Event date: 2019.12

    Language:English   Presentation type:Poster presentation  

    Venue:Orland  

  4. CBF-AMLの分子病態と治療 Invited

    石川裕一

    第80回日本血液学会学術集会 

     More details

    Event date: 2018.10

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:大阪   Country:Japan  

  5. Interim analysis of the New TARGET Observational Study 1, a prospective observational study for newly diagnosed CML in Japan

    Yuichi Ishikawa, Hitoshi Kiyoi, Ritsuro Suzuki, Tatsuya Kawaguchi, Naoto Takahashi, Kazuhito Yamamoto, Kazunori Ohnishi, Masahiro Kizaki, Tomoki Naoe, Itaru Matsumura

     More details

    Event date: 2017.10

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  6. Recent progress and problems in FLT3 inhibitor development Invited

    Y Ishikawa

    The Japan Adult Leukemia Study Group 30th Anniversary International Symposium 

     More details

    Event date: 2017.6

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

    Country:Japan  

  7. Cooperative mutations in core-binding factor-AML Invited International conference

    Y Ishikawa

    The 19th Korean Society of Hematology AML/MDS Working Party Symposium 

     More details

    Event date: 2016.10

    Language:English   Presentation type:Oral presentation (general)  

    Country:Korea, Republic of  

  8. Cooperative mutations in AML with recurrent genetic abnormalities Invited

     More details

    Event date: 2016.10

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

    Country:Japan  

  9. Cellular mechanisms for transferrin receptor endocytosis vital for terminal erythroid differentiation International conference

    Y Ishikawa, S. K. Tacheva-Grigorova, M Maeda, F Aguet, S Lee, M Ericsson, A Mullally, T Kirchhausen and T Maeda

     More details

    Event date: 2014.10

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  10. Cellular mechanisms for transferrin receptor endocytosis vital for terminal erythroid differentiation International conference

    Y Ishikawa, S. K. Tacheva-Grigorova, M Maeda, F Aguet, S Lee, M Ericsson, T Kirchhausen and T Maeda

    55th American Society of Hematology Annual Meeting and Exposition 

     More details

    Event date: 2013.12

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  11. Clathrin Assembly Protein CALM is Necessary for Leukemia cell Proliferation and Erythroid Development via Regulating Transferrin Receptor Endocytosis International conference

    Y Ishikawa, M Maeda, M Li, S Lee, J Feldstein, H Kiyoi, T Naoe, M Weiss, J Heuser and T Maeda

    53th American Society of Hematology Annual Meeting and Exposition 

     More details

    Event date: 2012.12

    Language:English   Presentation type:Oral presentation (general)  

    Country:United States  

  12. Clathrin assembly protein CALM plays a key role in erythroid differentiation via regulating transferrin receptor endocytosis International conference

    Y Ishikawa, M Maeda, M Li, S Lee, JE Heuser and T Maeda

    52th American Society of Hematology Annual Meeting and Exposition 

     More details

    Event date: 2011.12

    Language:English   Presentation type:Poster presentation  

    Country:United States  

▼display all

Research Project for Joint Research, Competitive Funding, etc. 6

  1. 本邦における初発急性前骨髄球性白血病に対するATRA・ATO併 用分化誘導療法の確立

    2021.10 - 2024.3

    国立研究開発法人日本医療研究開発機構(AMED)  日本医療研究開発機構研究費 革新的がん医療実用化研究事業 

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

  2. PDX 治療モデルを併用した治療抵抗性急性骨髄性白血病クローンの成立過程に生じる分子病態に基づく層別化システムの確立と標的治療薬開発に関する研究

    2020.4 - 2023.3

    国立研究開発法人日本医療研究開発機構(AMED)  日本医療研究開発機構研究費 革新的がん医療実用化研究事業 

  3. シングルセルバーコードラベル化PDX モデルによる難治性造血器腫瘍クローンの選択・進展過程に関与する分子病態の解明に関する研究

    2020.4 - 2023.3

    国立研究開発法人日本医療研究開発機構(AMED)  日本医療研究開発機構研究費 次世代がん医療創生研究事業 

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

  4. 骨髄系腫瘍における難治性クローンへの進展・選択過程に生じる分子病態の解明

    2019.8 - 2021.3

    国立研究開発法人日本医療研究開発機構(AMED)  日本医療研究開発機構研究費 次世代がん医療創生研究事業 

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

  5. 急性骨髄性白血病におけるPDXモデルで意義づけられた分子層別化システムの確立と臨床的実効性と有用性の検証

    2017.4 - 2020.3

    国立研究開発法人日本医療研究開発機構(AMED)  日本医療研究開発機構研究費 革新的がん医療実用化研究事業  

      More details

    Authorship:Coinvestigator(s) 

  6. 急性骨髄性白血病(AML)の発症・進展に関与するエンドサイトーシス機能異常と、それを標的とする治療法の開発

    2014.10 - 2016.3

    グラクソ・スミスクライン研究助成 

      More details

    Grant type:Competitive

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. 急性骨髄性白血病における変異型セリンプロテアーゼの高発現とその生物学的意義の解明

    Grant number:19K08810  2019.4 - 2022.3

    科学研究費補助金  基盤研究(C)

    石川 裕一

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

  2. クラスリン依存性エンドサイトーシス関連分子CALMを標的とした白血病治療の可能性

    Grant number:16K09845  2016.4 - 2019.3

    科学研究費補助金  基盤研究(C)

    石川 裕一

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

 

Teaching Experience (On-campus) 1

  1. 血液病「骨髄増殖性腫瘍」

    2021